Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic Corticosteroids for Severe Erythema Multiforme
NCT06266221Phase 3Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2024
- Primary completion
- Jun 2027
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, randomised, double-blind trial of prednisone and methylprednisolone injection in erythema multiforme (EM) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Time to success, Evaluation of Pain and 2 more. Planned start May 2024; status: not yet recruiting.
02
Drugs
prednisonemethylprednisolone injection
03
Conditions
erythema multiforme (EM)
Beyond the preview
Go deeper on NCT06266221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06266221.